2azb: Difference between revisions

Revision as of 09:13, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2azb.png

Template:STRUCTURE 2azb

HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3

Template:ABSTRACT PUBMED 16403521

About this StructureAbout this Structure

2AZB is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

ReferenceReference

Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3., Heaslet H, Kutilek V, Morris GM, Lin YC, Elder JH, Torbett BE, Stout CD, J Mol Biol. 2006 Mar 3;356(4):967-81. Epub 2005 Dec 20. PMID:16403521

Page seeded by OCA on Tue Jul 29 09:13:44 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2azb.gif|left|200px]]
+{{Seed}}
+[[Image:2azb.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2azb|  PDB=2azb  |  SCENE=  }}
-'''HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3'''
+===HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3===
-==Overview==
+<!--
-The development of resistance to anti-retroviral drugs targeted against HIV is an increasing clinical problem in the treatment of HIV-1-infected individuals. Many patients develop drug-resistant strains of the virus after treatment with inhibitor cocktails (HAART therapy), which include multiple protease inhibitors. Therefore, it is imperative that we understand the mechanisms by which the viral proteins, in particular HIV-1 protease, develop resistance. We have determined the three-dimensional structure of HIV-1 protease NL4-3 in complex with the potent protease inhibitor TL-3 at 2.0 A resolution. We have also obtained the crystal structures of three mutant forms of NL4-3 protease containing one (V82A), three (V82A, M46I, F53L) and six (V82A, M46I, F53L, V77I, L24I, L63P) point mutations in complex with TL-3. The three protease mutants arose sequentially under ex vivo selective pressure in the presence of TL-3, and exhibit fourfold, 11-fold, and 30-fold resistance to TL-3, respectively. This series of protease crystal structures offers insights into the biochemical and structural mechanisms by which the enzyme can overcome inhibition by TL-3 while recovering some of its native catalytic activity.
+The line below this paragraph, {{ABSTRACT_PUBMED_16403521}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 16403521 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_16403521}}
 ==About this Structure==
@@ Line 37: / Line 41: @@
 [[Category: Tl-3]]
 [[Category: V82a]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 19:39:26 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 09:13:44 2008''